Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. ESMO 2019 Congress

Poster Display session 2

1166 - Effect of prior cancer on survival outcomes for patients with pancreatic adenocarcinoma

Date

29 Sep 2019

Session

Poster Display session 2

Topics

Tumour Site

Pancreatic Adenocarcinoma

Presenters

Chaobin He

Citation

Annals of Oncology (2019) 30 (suppl_5): v253-v324. 10.1093/annonc/mdz247

Authors

C. He

Author affiliations

  • Department Of Hepatobiliary And Pancreatic Surgery, Sun Yat-sen University Cancer Center, 510060 - Guangzhou/CN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Login

Abstract 1166

Background

With the increasement of cancer survivors of prior cancers, more and more pancreatic ductal adenocarcinomas (PDACs) are developed as second primary cancers. Whether a history of prior cancer has an inferior impact on survival outcomes for patients with PDAC remains unknown. The aim of this study was to evaluate the prognostic factors and assess the survival impact of a history of prior cancer in patients with second primary PDAC.

Methods

Patients with PDAC were retrospectively selected from Surveillance, Epidemiology, and End Results (SEER) database. Overall survival (OS) and cancer-specific mortalities were compared between patients with or without prior cancer.

Results

From 2004 to 2015, 9235 patients with PDAC from SEER database were included, including 438 (4.74%) patients with a history of prior caner and 8797 (95.26%) patients without a history of prior cancer. A total of 438 cases with prior cancers and 4380 cases without prior cancers were matched successfully after propensity score matching (PSM). The median OS were both 7 months for PDAC patients with or without a history of prior cancer. These two groups of patients had similar survival rates and cancer-specific mortalities before or after PSM analyses. Multivariate analysis also showed that a history of prior cancer was not associated with OS in patients with PDAC.Table:

702P Overall survival rates of patients

Cancer typeNoOverall survival rates (%)HR (95% CI)pa
1-year (95% CI)2-year (95% CI)3-year (95% CI)
Whole cohort923536.7(36.6-36.7)18.7(18.6-18.7)11.7(11.6-11.7)
Without prior cancer879736.8(36.7-36.9)18.7(18.6-18.8)11.7(11.6-11.8)
Prostate cancer12635.6(35.3-35.8)21.4(21.1-21.5)13.3(13.1-13.5)1.137(0.928-1.393)0.171
Breast cancer11036.5(36.4- 36.6)16.6(16.5-16.7)14.7 (14.6-14.8)0.966(0.780-1.197)0.749
Renal and bladder cancer5135.6(35.5-35.7)21.4(21.3-21.5)13.3(13.2-13.4)1.004(0.732-1.376)0.980
Colon and rectum cancer4330.2(30.1-30.3)15.3(15.2-15.4)12.3(12.2-12.4)1.149(0.813-1.624)0.382
Uterine cancer2441.8(41.6-42.0)36.6(36.4-36.8)36.6(36.4-36.8)0.700(0.451-1.086)0.165
Lung cancer1649.2(49.0-49.4)16.4(16.2-16.6)8.2(8.1-8.4)0.865(0.531-1.408)0.572
Small intestinal cancer1544.0(43.7-44.3)11.7(11.5-11.9)11.7(11.5-11.9)0.948(0.533-1.687)0.855
Oral cancer1351.9(51.6-52.2)17.3(17.1-17.5)0.00.976(0.544-1.752)0.935
Stomach cancer1236.5(36.2-36.8)0.00.01.150(0.571-2.318)0.663
Hepatocellular cancer837.5(37.2-37.8)12.5(12.3-12.7)12.5(12.3-12.7)1.014(0.481-2.138)0.971
Matched cohort481835.1(35.0-35.2)18.2(18.1-18.2)11.7(11.7-11.7)
Without prior cancer438033.0(32.9-33.1)18.2(18.1-18.3)11.7(11.6-11.7)
Prostate cancer12635.6(35.3-35.5)21.4(21.1-21.5)13.3(13.1-13.5)0.967(0.708-1.318)0.826
Breast cancer11036.5(36.4- 36.6)16.6(16.5-16.7)14. (14.6-14.8)0.927(0.751-1.145)0.481
Renal and bladder cancer5135.6(35.5-35.7)21.4(21.3-21.5)13.3(13.2-13.4)0.967(0.709-1.318)0.826
Colon and rectum cancer4330.2(30.1-30.3)15.3(15.2-15.4)12.3(12.2-12.4)1.107(0.788-1.557)0.521
Uterine cancer2441.8(41.6-42.0)36.6(36.4-36.8)36.6(36.4-36.8)0.676(0.439-1.041)0.125
Lung cancer1649.2(49.0-49.4)16.4(16.2-16.6)8.2(8.048-8.352)0.842(0.520-1.364)0.504
Small intestinal cancer1544.0(43.7-44.3)11.7(11.5-11.9)11.7(11.5-11.9)0.908(0.517-1.596)0.739
Oral cancer1351.9(51.6-52.2)17.3(17.1-17.5)0.00.943(0.531-1.676)0.840
Stomach cancer1236.5(36.2-36.8)0.000.01.093(0.552-2.167)0.781
Hepatocellular cancer837.5(37.2-37.8)12.5(12.3-12.7)12.5(12.3-12.7)0.982(0.471-2.010)0.961

Conclusions

PDAC patients with a history of prior cancer had similar OS and cancer-specific mortalities with those without a cancer history. The inclusion of patients with prior cancer into clinical trials of PDAC may be considerable.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The author.

Funding

Grants: The National Natural Science Foundation of China (81171890; 81672390), and the Major National Scientific Research Projects of China (No. 2013CB910304).

Disclosure

The authors has declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.